ADVIL MINI-GELS CAPSULE
Land: Kanada
Språk: engelska
Källa: Health Canada
Produktens egenskaper
(SPC)
02-04-2020
Vissa dokument för denna produkt är för närvarande inte tillgängliga, du kan skicka en begäran till vår kundservice och vi kommer att meddela dig så snart vi kan få dem.
Skicka förfrågan.
Skicka förfrågan.
Aktiva substanser:
IBUPROFEN
Tillgänglig från:
GLAXOSMITHKLINE CONSUMER HEALTHCARE ULC
ATC-kod:
M01AE01
INN (International namn):
IBUPROFEN
Dos:
200MG
Läkemedelsform:
CAPSULE
Sammansättning:
IBUPROFEN 200MG
Administreringssätt:
ORAL
Enheter i paketet:
15G/50G
Receptbelagda typ:
OTC
Terapiområde:
OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS
Produktsammanfattning:
Active ingredient group (AIG) number: 0108883004; AHFS:
Bemyndigande status:
APPROVED
Tillstånd datum:
2019-02-04
Produktens egenskaper
_ _
_GlaxoSmithKline Consumer Healthcare Inc.. Page 1 of 39_
PRODUCT MONOGRAPH
ADVIL
®
MINI-GELS
Ibuprofen Capsules 200 mg (free acid and potassium salt)
Analgesic/Antipyretic
GlaxoSmithKine Consumer Healthcare Inc.
7333 Mississauga Road
Mississauga, Ontario
L5N 6L4
Date of Preparation:
February 26, 2004
Date of Revision :
April 2, 2020
Submission Control No: 236621
_ _
_GlaxoSmithKline Consumer Healthcare Inc. Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
..........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................5
ADVERSE REACTIONS
..................................................................................................10
DRUG INTERACTIONS
..................................................................................................14
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................18
ACTION AND CLINICAL PHARMACOLOGY
............................................................19
STORAGE AND STABILITY
..........................................................................................21
SPECIAL HANDLING INSTRUCTIONS
.......................................................................21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................21
PART II: SCIENTIFIC INFORMATION
................................................................................22
PHARMACEUTICAL INFORMATION
.............................................
Läs hela dokumentet
